Fig. 2: Kaplan–Meier estimate.

Comparison of the probability of staying in the study during 26 weeks of open-label treatment for the two ulotaront subgroups.

Comparison of the probability of staying in the study during 26 weeks of open-label treatment for the two ulotaront subgroups.